INDSWFTLAB · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 64/100 — Quality 36 · Valuation 82 · Momentum 100
| Share price | ₹233.99 |
| Market cap | ₹2,140 Cr |
| P/E ratio | 51.0 |
| P/B ratio | 1.5 |
| ROE | 47.7% |
| ROCE | 3.6% |
| Book value | ₹165.77 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹641 Cr | ₹41 Cr | 7.0% |
| 2025 | ₹562 Cr | ₹250 Cr | -3.0% |
| 2024 | ₹1,281 Cr | ₹421 Cr | 20.0% |
| 2023 | ₹1,207 Cr | ₹48 Cr | 19.0% |
| 2022 | ₹1,039 Cr | ₹-2 Cr | 19.0% |
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigra